Trial · NCT01354353
Results by group146
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 146
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | Aripiprazole | Days 10-16 | 5 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 160 mg LY2140023 | Days 10-16 | 6 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 240 mg LY2140023 | Days 10-16 | 9 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 320 mg LY2140023 | Days 10-16 | 11 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 400 mg LY2140023 | Days 10-16 | 11 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 480 mg LY2140023 | Days 10-16 | 11 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | Aripiprazole | Follow-up (Days 17-20) | 4 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 160 mg LY2140023 | Follow-up (Days 17-20) | 2 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 240 mg LY2140023 | Follow-up (Days 17-20) | 2 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 320 mg LY2140023 | Follow-up (Days 17-20) | 2 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 400 mg LY2140023 | Follow-up (Days 17-20) | 0 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 480 mg LY2140023 | Follow-up (Days 17-20) | 2 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | Aripiprazole | End of Study (Day 21) | 1 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 160 mg LY2140023 | End of Study (Day 21) | 1 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 240 mg LY2140023 | End of Study (Day 21) | 1 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 320 mg LY2140023 | End of Study (Day 21) | 1 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 400 mg LY2140023 | End of Study (Day 21) | 0 | participants | |
| Number of Participants With Clinically Significant Events (Physical Assessments and Clinical Lab Tests) | 480 mg LY2140023 | End of Study (Day 21) | 1 | participants | |
| Part A: Pharmacokinetics, Maximum Concentration (Cmax) | 160 mg LY2140023 | Day 10 (single dose) | 496 | Geometric Coefficient of Variation 65 | nanograms/milliliter (ng/mL) |
| Part A: Pharmacokinetics, Maximum Concentration (Cmax) | 240 mg LY2140023 | Day 10 (single dose) | 1170 | Geometric Coefficient of Variation 44 | nanograms/milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01354353/results